Cerulean :: Leadership In Nanopharmaceuticals

THE COMPANY

Focused on novel, nanotechnology-based therapeutics

Cerulean is a private biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, inflammation, and cardiovascular diseases.

Cerulean is pursuing three key strategies:

Achieving rapid and clinically significant human proof of concept with its technology.
Building a deep and diversified product pipeline and leveraging its proprietary nanotechnology platform.
Using a multi-faceted business model, with plans to retain some products for development and commercialization to achieve full company value creation, while at the same time collaborating on other products to leverage the resources and capabilities of partners.

Cerulean has assembled a world-class management team, board of directors, and scientific advisory board that collectively have a significant track record of business building, product development, and scientific breakthroughs.

Cerulean was founded in October of 2006 and is located in Cambridge, Massachusetts.

Cerulean was formerly known as Tempo Pharmaceuticals, Inc. view press release.

Our Mission:

Cerulean’s mission is to dramatically enhance patient outcomes in diseases of high unmet need through the application of nanotechnology and, in this way, enhance efficacy, lower toxicity and broaden the ability of combination therapy.

Nanotechnology will provide an avenue through which the traditional drug development pharmacokinetics and drug metabolism obstacles can be overcome by localizing drugs to their target sites at therapeutic concentrations for prolonged periods of time while at the same time reducing their systemic exposure.